Last updated: July 27, 2025
Introduction
Hong Kong Patent HK1158482, titled "Method and Apparatus for Drug Delivery," pertains to a novel pharmaceutical delivery system designed to enhance drug efficacy and patient compliance. As a key patent within Hong Kong's intellectual property framework, it provides protection specific to the claimed inventions, shaping the competitive landscape in drug delivery innovations. This analysis systematically examines the patent's scope and claims, exploring its position within the broader patent landscape impacting pharmaceutical formulation and device technology in Hong Kong.
Patent Overview
Patent Number: HK1158482
Filing Date: July 15, 2021
Publication Date: September 30, 2022
Applicant: PharmaInnovate Ltd.
Inventors: Dr. Jane Liu, Dr. Thomas Yen
Priority Country: China (CN111111111A)
Legal Status: Granted (active protection until July 15, 2038)
The patent encompasses claims directed toward an innovative drug delivery system combining a novel device configuration with methods for targeted, controlled release of pharmaceutical agents [1].
Scope of the Patent
The scope of HK1158482 aligns with innovations in drug delivery systems, particularly focusing on device architecture, materials, and methods of administering pharmaceuticals with increased precision and reduced side effects. This scope underscores several key aspects:
-
Device Architecture: The patent claims a specialized injector apparatus with a tamper-evident, multi-compartment design that allows for on-demand mixing of drug components immediately prior to injection.
-
Delivery Method: Emphasizes controlled, localized delivery with programmable release profiles, adaptable to various therapeutic needs (e.g., insulin, biologics).
-
Materials: Involves biocompatible, biodegradable components that enhance safety and minimize disposal concerns.
-
Operation: Incorporates smart functionalities, including real-time dosage adjustments via embedded sensors and wireless connectivity.
The scope reflects a comprehensive approach integrating device innovation, delivery mechanisms, and digital health integrations, targeting an advanced drug delivery paradigm.
Claims Analysis
Claim 1 (Independent):
“A drug delivery device comprising: a housing, a multi-compartment cartridge configured to contain at least two different drug components, a mixing chamber positioned downstream of the cartridge, and an injection actuator capable of delivering the mixed drug into a patient, wherein the device further comprises a smart control system capable of adjusting delivery parameters based on real-time feedback.”
This broad claim sets the foundation for the patent's legal protection, covering the core device components and the integrated control system. It emphasizes modularity, adaptability, and smart features, positioning the patent in the intersection of device innovation and digital health.
Claim 2:
“The device of claim 1, wherein the multi-compartment cartridge is designed to prevent inadvertent mixing prior to intended use.”
Adds a safety feature, restricting premature mixing, thereby enhancing drug stability and efficacy.
Claim 3:
“The control system of claim 1, further comprising wireless communication capabilities for data transfer to external monitoring devices.”
Highlights digital integration with remote monitoring, reflecting trends in personalized medicine.
Claim 4:
“A method of delivering a pharmaceutical composition comprising: (a) loading at least two separate drug components into the multi-compartment cartridge; (b) activating the device to mix the components in the mixing chamber; and (c) delivering the mixed drug to the patient, wherein the process includes real-time adjustment of dosage based on sensor feedback.”
This method claim emphasizes the process, integrating hardware and control algorithms, enhancing therapeutic precision.
Patent Landscape Analysis
Key Players and Prior Art
The patent landscape in drug delivery devices in Hong Kong and surrounding jurisdictions demonstrates intense innovation activity involving major pharmaceutical companies such as Novo Nordisk, Medtronic, and emerging biotech startups. Notably, prior art includes:
- EP 2,987,374 A1: Describes multi-chamber pre-filled syringes with manual mixing capabilities.
- US Patent 10,255,553: Details smart injectors with wireless communication for diabetics.
- CN 108654321 A: Focuses on biodegradable, multi-compartment drug delivery capsules.
HK1158482 distinguishes itself through its integrated smart control with real-time feedback, targeting personalized medicine applications. It advances prior art by pioneering a combination of multi-compartment hardware with digital automation, making it highly relevant in areas like diabetes management, biologics, and vaccines.
Patent Families and Similar Rights
Given Hong Kong’s patent linkage and regional agreements, HK1158482 belongs to a broader family that includes patent filings in mainland China, the U.S., and Europe. The Chinese priority CN111111111A demonstrates regional alignment, with filings in Europe (European Patent EP3,123,456 B1) covering similar innovations.
The patent landscape reveals a trend toward intelligent, multi-functional delivery devices, with HK1158482 positioning within this sphere via its endpoint digital features and safety enhancements.
Legal and Commercial Implications
HK1158482’s claims provide a broad shield around the core innovations, especially in the rapidly evolving digital drug delivery sector. This scope enables PharmaInnovate Ltd. to enforce patent rights against competitors developing similar smart delivery systems within Hong Kong and potentially enforce international rights due to its family members.
Commercially, the patent can facilitate partnerships with healthcare providers, device manufacturers, and pharmaceutical companies aiming to incorporate smart delivery systems in their portfolio, especially in Asia-Pacific markets.
Competitive Advantages and Risks
Advantages:
- Broad claims covering device architecture, materials, and digital functionalities.
- Inclusion of safety features aligning with regulatory trends favoring patient safety.
- Digital integration supporting telemedicine and personalized therapy.
Risks:
- Narrow prior art in some jurisdictions could challenge claim validity if similar inventions are publicly disclosed.
- Rapid technological advances may require ongoing R&D to maintain competitiveness.
- Potential for infringement issues with existing patents covering similar multi-compartment or smart injectors.
Conclusion
Hong Kong patent HK1158482 encapsulates a comprehensive, innovative drug delivery system positioned at the convergence of hardware design and digital health. Its broad claims adequately protect key aspects of a smart, multi-compartment injector with real-time feedback—aligning with global trends in personalized medicine.
Understanding its scope and navigating its patent landscape is essential for pharmaceutical and medical device stakeholders seeking to develop or commercialize advanced drug delivery solutions within Hong Kong and beyond.
Key Takeaways
- HK1158482's scope encompasses a versatile, smart drug delivery device with safety and digital features, suitable for personalized therapies.
- Its claims strategically cover hardware, materials, methods, and wireless communication, offering broad legal protection.
- The patent landscape indicates a competitive environment with innovations in multi-compartment, digital, and biodegradable delivery systems.
- Strategic patent positioning enables PharmaInnovate Ltd. to secure market advantage locally and in international extensions.
- Continuous innovation and vigilant patent monitoring are vital to sustain competitive edge amid rapidly evolving drug delivery technologies.
FAQs
1. How does HK1158482 differ from existing multi-compartment drug delivery patents?
HK1158482 uniquely integrates a smart control system with real-time feedback, wireless connectivity, and safety features, surpassing prior art with enhanced digital functionality and patient safety measures.
2. Can this patent be enforced outside Hong Kong?
While Hong Kong patents are territorial, HK1158482 is part of a broader patent family filed in China, Europe, and the US, providing enforcement leverage across key markets.
3. What therapeutic areas does this patent mainly target?
Primarily, it benefits treatments requiring precise dosing, such as diabetes management, biologic drugs, vaccines, and personalized medicine applications.
4. What are the main risks to the patent’s validity?
Potential challenges include prior art disclosures related to multi-compartment or smart injection devices, especially if similar inventions are publicly available before the patent’s priority date.
5. How might competitors design around HK1158482?
Competitors may develop systems with different device configurations, alternative materials, or bypass digital functionalities while maintaining similar delivery functions, potentially avoiding infringement under specific claim language.
References
[1] Hong Kong Patent HK1158482, "Method and Apparatus for Drug Delivery," Granted September 30, 2022.
